<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02269228</url>
  </required_header>
  <id_info>
    <org_study_id>9.131</org_study_id>
    <nct_id>NCT02269228</nct_id>
  </id_info>
  <brief_title>Tolerability of Asasantin in Healthy Female and Male Subjects</brief_title>
  <official_title>Tolerability of a Two Week Treatment With Asasantin Extended Release 200/25 mg Capsules b.i.d., Compared to Reduced Dose During the First Week of Treatment in a Double-blind, Randomised, Placebo Controlled Parallel Group Comparison Trial in Healthy Female and Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      To investigate the occurrence of dipyridamole associated headaches in healthy subjects using
      a titration scheme or not
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2000</start_date>
  <primary_completion_date type="Actual">April 2000</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulated headache (intensity x duration) per day based on mean severity per waking hours expressed as area under the curve (AUC)</measure>
    <time_frame>Day 14 after first drug administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects experiencing moderate/severe headache</measure>
    <time_frame>Day 14 after first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects experiencing headache</measure>
    <time_frame>Day 14 after first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulated headache (intensity x duration) per day based on maximum severity per day expressed as AUC</measure>
    <time_frame>Day 14 after first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of acetylsalicylic acid (ASA) 500 used to cut headache</measure>
    <time_frame>Day 14 after first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in vital signs</measure>
    <time_frame>Pre-dose and day 17 after first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in laboratory tests</measure>
    <time_frame>Pre-dose and day 17 after first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in 12-lead ECG</measure>
    <time_frame>Pre-dose and day 17 after first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in physical examination</measure>
    <time_frame>Pre-dose and day 17 after first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>Up to day 17 after first drug administration</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Asasantin ER</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered once daily (days 1 to 7), followed by twice daily administration (days 8 to 14)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Asasantin ER, administered twice daily from day 1 to day 14</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Asasantin ER</intervention_name>
    <arm_group_label>Asasantin ER</arm_group_label>
    <arm_group_label>Asasantin ER, administered twice daily from day 1 to day 14</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All participants in the study should be healthy females/males, range from 18 to 55
             years of age and be within a Broca Index of ≥ - 20 % and ≤ + 20 %

          -  Prior to admission to the study all subjects will have given, in accordance with good
             clinical practice (GCP) and the local legislation, their written informed consent.

        Exclusion Criteria:

          -  Subjects will be excluded from the study if the results of the medical examination
             (including blood pressure, pulse rate and ECG) deviating from normal and are of
             clinical relevance

          -  Subjects with known gastrointestinal, hepatic, renal, respiratory, cardiovascular,
             metabolic, immunological or hormonal disorders

          -  Subjects with diseases of the central nervous system (such as epilepsy) or with
             psychiatric disorders or neurological disorders

          -  Subjects with known history of orthostatic hypotension, fainting spells or blackouts

          -  Subjects with chronic or relevant acute infections

          -  Subjects with history of allergy/hypersensitivity (including drug allergy) which is
             deemed relevant to the trial as judged by the investigator

          -  Subjects who have taken a drug with a long half-life (&gt; 24 hours) (≤ 1 month prior to
             administration or during the trial)

          -  Subjects who received any other drugs which might influence the results of the trial
             (≤ 10 days prior to administration or during the trial)

          -  Subjects who have participated in another study with an investigational drug (≤ 1
             month prior to administration or during the trial)

          -  Subjects who smoke more than 15 cigarettes or 4 cigars or 4 pipes/day

          -  Subjects who are not able to refrain from excessive consumption of methylxanthine
             containing drinks or food

          -  Subjects who drink more than 60 g of alcohol per day

          -  Subjects who are dependent on drugs

          -  Subjects who have donated blood (&gt; 400 ml) (≤ 4 weeks prior to administration or
             during the trial)

          -  Subjects who have participated in excessive physical activities (≤ 5 days prior to
             administration or during the trial)

        For female subjects:

          -  Pregnancy

          -  Positive pregnancy test

          -  No adequate contraception (acceptable: e.g. sterilisation, intrauterine devices (IUD),
             oral contraceptives, condoms)

          -  Inability to maintain this adequate contraception during the whole study period

          -  Lactation period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
  </link>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 20, 2014</study_first_submitted>
  <study_first_submitted_qc>October 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2014</study_first_posted>
  <last_update_submitted>October 20, 2014</last_update_submitted>
  <last_update_submitted_qc>October 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin, Dipyridamole Drug Combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

